United Advisor Group’s Regeneron Pharmaceuticals REGN Stock Holding History

United Advisor Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$259K	Buy	335 +4	+1%	+$3.06K	0.03%	426
2025 Q4	$256K	Sell	331 -130	-28%	-$88.3K	0.03%	414
2025 Q3	$259K	Buy	461 +76	+20%	+$43K	0.03%	396
2025 Q2	$202K	Buy	385 +4	+1%	+$2.23K	0.03%	377
2025 Q1	$242K	Sell	381 -74	-16%	-$50.9K	0.05%	308
2024 Q4	$324K	Sell	455 -94	-17%	-$78.9K	0.06%	283
2024 Q3	$577K	Buy	549 +224	+69%	+$249K	0.13%	161
2024 Q2	$342K	Buy	325 +30	+10%	+$29.1K	0.11%	185
2024 Q1	$284K	Buy	+295	New	+$281K	0.11%	168

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

United Advisor Group's REGN Position: Q1 2026 in Review

United Advisor Group increased its Regeneron Pharmaceuticals (REGN) stake by 1.2% in Q1 2026, buying an estimated $3.06K and bringing the position to 335 shares worth $259K. The position accounts for 0.03% of the portfolio, ranked #426.

United Advisor Group first reported a position in REGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $577K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

United Advisor Group held 335 shares of Regeneron Pharmaceuticals worth $259K as of Q1 2026.
United Advisor Group bought 4 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.06K.
Regeneron Pharmaceuticals made up 0.03% of United Advisor Group's portfolio in Q1 2026, its #426 holding.
United Advisor Group first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
United Advisor Group's Regeneron Pharmaceuticals position peaked at $577K in Q3 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on United Advisor Group's 13F filing for Q1 2026, filed 17 Apr 2026.